Xenetic Biosciences

94 articles with Xenetic Biosciences

• Xenetic Biosciences, Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update

  8/12/2022

  Xenetic Biosciences, Inc. today reported its financial results for the second quarter of 2022 and provided a business update.

• 

  AbbVie and Sosei Lead Slate of Early August R&D Deals

  8/2/2022

  AbbVie and Sosei add neurological targets in new deal, TransCode and MD Anderson partner on RNA cancer therapies and Xenetic and VolitionRx unite to develop NETs-targeted therapies against cancer.

• Xenetic Biosciences, Inc. and VolitionRx Limited Collaborate to Develop NETs-Targeted Adoptive Cell Therapies for the Treatment of Cancer

  8/2/2022

  Xenetic Biosciences, Inc. today announced a research and development collaboration to develop Neutrophil Extracellular Traps targeted, adoptive cell therapies for the treatment of cancer.

• Xenetic Biosciences, Inc. Engages Catalent for Clinical Manufacturing to Advance DNase-Based Oncology Platform Towards Phase 1 Study

  7/7/2022

  Xenetic Biosciences, Inc. today announced it has entered into a manufacturing agreement with Catalent Pharma Solutions LLC ("Catalent"), which will include cGMP manufacturing for the Company's recombinant protein, Human DNase I.

• Xenetic Biosciences, Inc. to Participate in the Virtual Investor Innovation in Oncology Event

  6/2/2022

  Xenetic Biosciences, Inc. announced that it will participate in the Virtual Investor Innovation in Oncology Event on Thursday, June 9, 2022 at 11:00 AM ET.

• Xenetic Biosciences, Inc. to Present at the H.C. Wainwright Global Investment Conference

  5/18/2022

  Xenetic Biosciences, Inc. a biopharmaceutical company focused on advancing innovative immune-oncology technologies for the treatment of hard to treat cancers, today announced that Jeffrey F. Eisenberg, Chief Executive Officer of Xenetic, will present at the H.C. Wainwright Global Investment Conference.

• Xenetic Biosciences, Inc. Reports First Quarter 2022 Financial Results and Provides Business Update

  5/12/2022

  Xenetic Biosciences, Inc. reported its financial results for the first quarter of 2022 and provided a business update.

• Xenetic Biosciences, Inc. Expands Oncology Pipeline with In-Licensing of DNase Based Oncology Platform Comprising Multiple Therapeutic Modalities

  4/27/2022

  Xenetic Biosciences, Inc. announced that it has entered into exclusive license and sublicense agreements with CLS Therapeutics to develop its interventional DNase based oncology platform, which is aimed at improving outcomes of existing treatments, including immunotherapies.

• Xenetic Biosciences, Inc. Reports Full Year 2021 Financial Results and Provides Business Update

  3/23/2022

  Xenetic Biosciences, Inc., a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, reported its financial results for the full year 2021 and provided a corporate update.

• Xenetic Biosciences, Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update

  11/12/2021

  Xenetic Biosciences, Inc. today reported its financial results for the third quarter of 2021 and provided a corporate update.

• Xenetic Biosciences, Inc. Receives Notice of Allowance for XCART(TM) Patent

  9/9/2021

  Xenetic Biosciences, Inc. today announced the United States Patent and Trademark Office (USPTO) has issued Xenetic a Notice of Allowance for U.S. patent application number 16/983,491 entitled, "Articles and Methods Directed to Personalized Therapy of Cancer."

• Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

  9/8/2021

  Xenetic Biosciences, Inc. today announced that Jeffrey F. Eisenberg, Chief Executive Officer of Xenetic will present at the virtual H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13-15, 2021.

• Xenetic Biosciences, Inc. Reports Second Quarter 2021 Financial Results and Provides Business Update

  8/13/2021

  Xenetic Biosciences, Inc. today reported its financial results for the second quarter of 2021 and provided a corporate update.

• Xenetic Biosciences, Inc. Announces Closing of $12.5 Million Private Placement Priced at a Premium to Market

  7/28/2021

  Xenetic Biosciences, Inc. announced the closing of its previously announced private placement with a single healthcare-focused institutional investor for 4,629,630 shares of its common stock at a purchase price per share of $2.70, priced at-the-market under Nasdaq rules.

• Xenetic Biosciences, Inc. Announces $12.5 Million Private Placement Priced at a Premium to Market

  7/26/2021

  Xenetic Biosciences, Inc., a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the purchase of 4,629,630 shares of its common stock at a purchase price per share of $2.70, in a private placement priced at-the-market under Nasdaq rules.

• Xenetic Biosciences, Inc. Reports First Quarter 2021 Financial Results

  5/12/2021

  Licensing Partners Leveraging PolyXen® Platform Technology Continue To Make Clinical, Regulatory and Commercial Advancement

• Xenetic Biosciences, Inc. to Present at the Q2 Virtual Investor Summit

  5/10/2021

  Xenetic Biosciences, Inc. , a biopharmaceutical company focused on advancing XCART, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, announced today that Jeffrey Eisenberg, Chief Executive Officer of Xenetic will present the Q2 Virtual Summit on Tuesday, May 18th at 3:30 PM ET.

• Xenetic Biosciences, Inc. Receives Approval to Commence Exploratory Study of XCART(TM)

  3/29/2021

  - Data from the study to provide valuable insights as the Company advances XCART lead program in Non-Hodgkin lymphoma (NHL) towards Investigational New Drug (IND) filing in the United States

• Xenetic Biosciences, Inc. Reports Fourth Quarter and Full Year 2020 Financial Results

  3/17/2021

  Xenetic Biosciences, Inc. today reported its financial results for the fourth quarter and full year 2020, and provided a corporate update.

• Xenetic Biosciences, Inc. to Present at the H.C. Wainwright Global Life Sciences Conference

  3/3/2021

  Xenetic Biosciences, Inc. a biopharmaceutical company focused on advancing a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, announced today that Jeffrey Eisenberg, Chief Executive Officer of Xenetic will present at the virtual H.C. Wainwright Global Life Sciences Conference taking place March 9-10, 2021.